Back to Agenda
ePI – Setting Tomorrow’s Labelling and Regulatory Operations Framework
Session Chair(s)
Aimad Torqui
Division Head Medicines Evaluation Board
Medicines Evaluation Board, Netherlands
The paradigm shift from document based processes to (semi)-structured date for electronic product information, will create new opportunities for medicines information dissemination withininhealth systems. Regulatory efficiencies and operational excellence will also be achieved for the benefit of Regulators and Industry via a coherent and consistent implementation of ePI across Europe with significant consequential value for patients and healthcare providers. To achieve this, a standard should be adopted in the creation, submission and review process. As Regulatory data becomes the primary communication form between marketing authorisation holders and Health Authorities, its accuracy, completeness and reliability is more important than ever. Post-approval ePI also presents opportunities for leveraging advances in AI and natural language processing, which have the potential to enable intelligent labelling solutions.Therefore, this session will explore the requirements and skills sets needed for rolling out and implementing ePI within MAHs and Health Authorities. The session will also demonstrate how AI can potentially play a role in future ePI based operations.
Speaker(s)
ePI Setting the Scene: 'Problem Statement' and Next Steps
Elizabeth Scanlan, PhD, MSc
European Medicines Agency, Netherlands
ePI Product Owner
Expanding Beyond ePI: Outline of Gravitate Health
Deborah Bebbington
Bayer Plc, United Kingdom
Head Global Labeling
Post Approval Future Looking: Utilisation of AI
Paul Walsh
Accenture LLP, Ireland
Senior Manager
Panelist
Fakhredin Sayed Tabatabaei, MD, PhD
MEB, Netherlands
Senior Assessor
Have an account?